Sign In
Buy APLS
$41.03
+0 (+0%)
At Close: Jun 03, 2026
Biogen to buy Apellis Pharmaceuticals for $5.6 billion
07:05am, Tuesday, 31'st Mar 2026
Biogen said on Tuesday it has agreed to acquire Apellis Pharmaceuticals for about $5.6 billion in cash.
CAMBRIDGE, Mass. and WALTHAM, Mass., March 31, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced the companies have entered into a de
Why Is Apellis Pharmaceuticals (APLS) Down 17.3% Since Last Earnings Report?
12:32pm, Thursday, 26'th Mar 2026
Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock?
This New $193 Million Bet Targets a Biotech With $689 Million in Revenue and a Potential Turnaround Story
07:19pm, Saturday, 21'st Mar 2026
RTW Investments established a new position in Apellis Pharmaceuticals, adding 7,666,764 shares during the fourth quarter. The quarter-end value of the Apellis stake was $192.59 million, reflecting the
Pre-Market Stock Futures: Futures are trading higher as we get ready to conclude another dreadful week on Wall Street. The song remains the same as soaring oil prices, another week of war with Iran, a
Apellis Pharmaceuticals Details SYFOVRE, EMPAVELI Growth Plans and FcRn Gene-Editing Push at TD Cowen Conf.
04:30am, Tuesday, 03'rd Mar 2026
Apellis Pharmaceuticals (NASDAQ: APLS) executives outlined a three-part strategy for the company at TD Cowen's 46th Annual Healthcare Conference, emphasizing a "durable and resilient" SYFOVRE franchis
Apellis Pharmaceuticals, Inc. (APLS) Presents at TD Cowen 46th Annual Health Care Conference Transcript
12:57pm, Monday, 02'nd Mar 2026
Apellis Pharmaceuticals, Inc. (APLS) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors
07:00am, Monday, 02'nd Mar 2026
WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) announced today that Mikael Dolsten, M.D.
Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y
09:56am, Wednesday, 25'th Feb 2026
APLS posts wider-than-expected Q4 loss as Syfovre sales slip 8%, but revenues top estimates and Empaveli surges 50% on a strong new indication launch.
Apellis Pharmaceuticals, Inc. (APLS) Surpasses Q4 Earnings and Revenue Estimates
12:01pm, Tuesday, 24'th Feb 2026
Apellis Pharmaceuticals, Inc. (APLS) came out with quarterly earnings of $0.47 per share, beating the Zacks Consensus Estimate of a loss of $0.4 per share. This compares to a loss of $0.29 per share a
Apellis Pharmaceuticals (APLS) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
12:01pm, Tuesday, 24'th Feb 2026
While the top- and bottom-line numbers for Apellis Pharmaceuticals (APLS) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its ke
Apellis Pharmaceuticals, Inc. (APLS) Q4 2025 Earnings Call Transcript
11:48am, Tuesday, 24'th Feb 2026
Apellis Pharmaceuticals, Inc. (APLS) Q4 2025 Earnings Call Transcript
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
07:05am, Tuesday, 24'th Feb 2026
WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its fourth quarter and full year 2025 financial results and business highlights.
Apellis Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference
07:00am, Monday, 23'rd Feb 2026
WALTHAM, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will participate in a webcast fireside chat at the TD Cowen 46th Annual
Apellis Pharmaceuticals (APLS) Expected to Announce Earnings on Tuesday
03:26am, Sunday, 22'nd Feb 2026
Apellis Pharmaceuticals (NASDAQ: APLS - Get Free Report) is anticipated to release its Q4 2025 results before the market opens on Tuesday, February 24th. Analysts expect Apellis Pharmaceuticals to pos
